Cassava Sciences (SAVA) stock gains as company completes Phase 3 trial for Alzheimer's candidate simufilam, to release topline data.
https://seekingalpha.com/news/4295466-cassava-sciences-stock-alzheimers-update
Cassava Sciences (SAVA) stock gains as company completes Phase 3 trial for Alzheimer's candidate simufilam, to release topline data.
https://seekingalpha.com/news/4295466-cassava-sciences-stock-alzheimers-update
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.